Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2915MR)

This product GTTS-WQ2915MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2915MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3391MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ3670MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ13443MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ14863MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ5865MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ14377MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ7602MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ11514MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MFGR1877S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW